| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| References | |
|---|---|
| Additional Infomation |
XL844 is being investigated for its application in the treatment of solid tumors. XL844 is a drug for solid tumors. XL844 is a potent inhibitor of checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to various DNA damage agents. Known drug targets of XL844 include serine/threonine protein kinases Chk1 and Chk2. The checkpoint kinase inhibitor XL844 is a synthetic small molecule inhibitor of checkpoint kinases 1 and 2 (Chk1 and Chk2) with potential antitumor activity. XL844 binds to and inhibits the activity of Chk1 and Chk2, thereby inhibiting cell cycle arrest, progressive DNA damage, inhibiting DNA repair, and ultimately inducing tumor cell apoptosis. This drug also inhibits vascular endothelial growth factor receptor 1 (VEGFR1) and vascular endothelial growth factor receptor 3 (VEGFR3), which are important mediators of tumor angiogenesis and lymphogenesis, respectively. In cases of severe damage or delayed repair, these checkpoint signaling pathways may also trigger apoptosis. Normal functions of Chks include initiating cell cycle arrest and upregulating transcriptional genes involved in DNA excision repair and dNTP synthesis.
Drug Indication It has been studied for the treatment of cancer/tumor (not specified) and solid tumors. Mechanism of Action XL844 is a potent inhibitor of checkpoint kinases CHK1 and CHK2, which induce cell cycle arrest in response to various DNA damaging agents. Activation of these checkpoints after DNA damage promotes DNA repair and protects tumor cells from the cytotoxic effects of chemotherapy and radiotherapy. XL844 can deactivate these cell cycle arrests and enhances the killing effect of various chemotherapeutic agents and radiation on tumor cells in vitro. XL844 exhibits favorable pharmacokinetic properties and oral bioavailability, and in in vivo tumor models, it can improve the efficacy of chemotherapeutic agents without increasing systemic toxicity. |
| Molecular Formula |
C14H17N5O2
|
|---|---|
| Molecular Weight |
287.32
|
| Exact Mass |
287.138
|
| CAS # |
631864-00-1
|
| PubChem CID |
10016910
|
| Appearance |
Typically exists as solids at room temperature
|
| Hydrogen Bond Donor Count |
3
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
21
|
| Complexity |
316
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C1=CC=C(C(=C1)NC(=O)NC2=NC=CN=C2)OCCCN
|
| InChi Key |
UVSSZSQSZGKMAL-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H17N5O2/c15-6-3-9-21-12-5-2-1-4-11(12)18-14(20)19-13-10-16-7-8-17-13/h1-2,4-5,7-8,10H,3,6,9,15H2,(H2,17,18,19,20)
|
| Chemical Name |
1-[2-(3-aminopropoxy)phenyl]-3-pyrazin-2-ylurea
|
| Synonyms |
EXEL-9844
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4804 mL | 17.4022 mL | 34.8044 mL | |
| 5 mM | 0.6961 mL | 3.4804 mL | 6.9609 mL | |
| 10 mM | 0.3480 mL | 1.7402 mL | 3.4804 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Link: https://clinicaltrials.gov/ct2/show/NCT00475917
Conditions:Cancer|LymphomaLink: https://clinicaltrials.gov/ct2/show/NCT00234481
Conditions:Chronic Lymphocytic Leukemia|Small Lymphocytic LymphomaProducts are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
